
|Articles|September 5, 2019
KPMG Survey Reveals CEOs See Financial Drivers for M&A
Advertisement
KPMG, a professional services firm providing business solutions and audit, tax, and advisory services, released its CEO Outlook survey results. The survey found that low interest rates and high stock valuations are fueling U.S. life sciences CEOs’ growing appetite for mergers and acquisitions.
Some key takeaways from the survey include:
- 43% of U.S. life sciences CEOs say they have a “high appetite” for M&A, an increase from 33% a year ago.
- 58% of U.S. CEOs said using cheap financing, such as low interest rates before they rise, are a primary driver of deals during the next three years.
- 48% of those in the U.S. pointed to favorable stock valuations as a motivator for deals.
- 44% of life sciences CEOs globally found that business-model transformation was the leading driver of M&A, followed by improving market share and also capitalizing on low interest rates (both 39%).
- Cost cutting was seen as a motivator equally among global and U.S. CEOs (39%).
To view the full survey, visit
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Origins of Nuvation Bio’s Deal with Daichii Sankyo for the Rights to Safusidenib in Japan
2
Pharma M&A Roundup: AstraZeneca Enters License Deal with Dizal Pharmaceutical, Chai Discovery Enters Collaboration with Novartis, Innovent Biologics Enters License Agreement with Spero Therapeutics
3
FDA Approves Leqembi Iqlik Subcutaneous Injection for Early Alzheimer’s Disease
4
Educating Patients About GLP-1s: Q&A with Kristen Hartzell, PharmD
5




